IRD
Opus Genetics, Inc. · Healthcare · Market cap $502.5M
Insiders sold $214K net in the last 90 days ·4 sellers, 0 buyers· 1 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 8, 2026
Insider Buying
$324K
reported purchases (SEC code P)
Insider Selling
$16.6M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Sep 11, 2026
Gagnon Robert E.
Opus Genetics, Inc. (IRD) has 44 SEC Form 4 filings (47 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Sep 11, 2026.
Inside the rolling window, 8 insiders at Opus Genetics, Inc. reported 1 open-market purchase totaling $324K and 17 open-market sales totaling $16.6M. The most active filer is Chief Financial Officer Gagnon Robert E. with 3 filings. Insiders have net sold $8.0M over the trailing 6 months. The most recent open-market filing is a sale of 28,000 shares by Chief Financial Officer Gagnon Robert E., dated Sep 3, 2026, worth $127K.
- Industry:Biotechnology
- CEO:George Magrath
- Employees:18
- HQ:Durham, MI, US
- IPO:2015-01-19
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 28,000 | $127K | Sep 8 | +39.2% | SEC ↗ | |
Gagnon Robert E.First in 3 months | Chief Financial Officer | Sale | 7,783 | $23K | Jul 27 | +80.3% | SEC ↗ |
Magrath GeorgeFirst in 3 months | Chief Executive Officer | Sale | 9,475 | $28K | Jul 27 | +80.3% | SEC ↗ |
SCHACHLE JOSEPH KFirst in 3 months | Chief Operating Officer | Sale | 4,644 | $14K | Jul 27 | +80.3% | SEC ↗ |
YERXA BENJAMIN RFirst in 3 months | President | Sale | 7,429 | $22K | Jul 27 | +80.3% | SEC ↗ |
Foundation Fighting Blindness Retinal Degeneration FundFirst in 5 months | See Remarks | Sale | 1,700,000 | $7.4M | May 20 | +36.0% | SEC ↗ |
| Chief Scientific & Dev. Ofc. | Sale | 7,542 | $39K | Apr 27 | +18.0% | SEC ↗ | |
YERXA BENJAMIN RFirst filing | President | Sale | 7,470 | $39K | Apr 27 | +18.0% | SEC ↗ |
Gagnon Robert E.First in 4 months | Chief Financial Officer | Sale | 7,842 | $41K | Apr 27 | +18.0% | SEC ↗ |
| Head of Fin. Quality Assurance | Sale | 1,641 | $9K | Apr 27 | +18.0% | SEC ↗ | |
| Chief Executive Officer | Sale | 9,511 | $50K | Apr 27 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 4,697 | $25K | Apr 27 | — | SEC ↗ | |
Jayagopal AshwathFirst filing | Chief Scientific & Dev. Ofc. | Sale | 3,719 | $19K | Mar 18 | — | SEC ↗ |
Magrath GeorgeFirst filing | Chief Executive Officer | Sale | 24,438 | $127K | Mar 18 | — | SEC ↗ |
SCHACHLE JOSEPH KFirst filing | Chief Operating Officer | Sale | 3,719 | $20K | Mar 18 | — | SEC ↗ |
Zaremba Rabourn AmyFirst filing | Head of Fin. Quality Assurance | Sale | 2,816 | $15K | Mar 18 | — | SEC ↗ |
Gallagher CamFirst filing | Director | Purchase | 164,000 | $324K | Dec 31 | — | SEC ↗ |
| See Remarks | Sale | 4,000,000 | $8.6M | Dec 11 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does IRD have?
Opus Genetics, Inc. (IRD) has 44 SEC Form 4 filings (47 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Sep 11, 2026.
When was the most recent SEC Form 4 filing for IRD?
The most recent Form 4 filing for IRD on Tracefour is dated Sep 11, 2026.
Who is the most active insider at IRD?
The most active SEC Form 4 filer at IRD in the rolling window is Chief Financial Officer Gagnon Robert E., with 3 filings.
What is the net insider flow at IRD over the last 6 months?
Over the trailing 180 days, insiders at IRD have net sold $8.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at IRD in the current window?
Inside the rolling window, insiders at IRD bought $324K and sold $16.6M based on SEC Form 4 filings.
Can I get alerts for IRD insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Opus Genetics, Inc. (IRD). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Opus Genetics, Inc. is in the Healthcare sector.